KalVista Pharmaceuticals, Inc. (KALV)

KalVista Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is May - April.

Fiscal Year	FY	FY	FY	FY	FY
Period Ending	Apr 30, 2025	Apr 30, 2024	Apr 30, 2023	Apr 30, 2022	Apr 30, 2021
Net Income	-183.44	-126.64	-92.91	-82.34	-46.24
Depreciation & Amortization	0.94	0.82	0.72	0.56	0.54
Stock-Based Compensation	12.29	21.92	9.92	11.09	7.12
Other Adjustments	2.27	-0.49	-0.41	4.88	0.07
Change in Receivables	-3.62	8.18	-2.32	-5.2	7.46
Changes in Accounts Payable	-4.97	4.32	1.11	1.69	0.15
Changes in Accrued Expenses	14.43	3.21	1.93	0.47	0.98
Changes in Unearned Revenue	10.56	-	-	-	-
Changes in Other Operating Activities	-1.36	-0.54	6.69	-9.28	-0.24
Operating Cash Flow	-152.91	-89.23	-75.26	-78.13	-30.17
Capital Expenditures	-0.43	-0.04	-1.2	-0.93	-0.08
Purchases of Intangible Assets	-0.5	-0.4	-	-	-
Purchases of Investments	-30.57	-189.23	-98.25	-136.92	-201.21
Proceeds from Sale of Investments	122.52	104.96	140.86	195.71	53.64
Investing Cash Flow	91.02	-84.72	41.42	57.86	-147.65
Issuance of Common Stock	61.69	150.71	58.12	1.58	212.12
Net Common Stock Issued (Repurchased)	61.69	150.71	58.12	1.58	212.12
Other Financing Activities	98.04	-	-	-	-
Financing Cash Flow	159.73	150.71	58.12	1.58	212.12
Effect of Exchange Rate Changes on Cash and Cash Equivalents	2.64	-1.21	1.24	-1.17	0.51
Net Cash Flow	100.48	-24.45	25.51	-19.86	34.8
Free Cash Flow	-153.34	-89.27	-76.46	-79.07	-30.25
Free Cash Flow Per Share	-3.09	-2.43	-2.74	-3.23	-1.58
Levered Free Cash Flow	-164.28	-118.88	-83.66	-89.83	-44.9
Unlevered Free Cash Flow	-172.37	-132.68	-101.62	-104.1	-56.58

Updated Sep 11, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q